Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +0.39%83 EV-to-FCF is 10.08 as of Jul. 21, 2026, which is 47% below its 10-year median of 19.06. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 566 Drug Manufacturers companies, TTY Biopharm Co ranks better than 74.2% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TTY Biopharm Co's Enterprise Value is NT$17,960 Mil.
TTY Biopharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was NT$1,781 Mil. Therefore, TTY Biopharm Co's EV-to-FCF for today is 10.08.
The historical rank and industry rank for TTY Biopharm Co's EV-to-FCF or its related term are showing as below:
ROCO:4105'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.27 Med: 19.06 Max: 53.26
Current: 10.08
During the past 13 years, the highest EV-to-FCF of TTY Biopharm Co was 53.26. The lowest was 9.27. And the median was 19.06.
ROCO:4105's EV-to-FCF is ranked better than 74.2% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs ROCO:4105: 10.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TTY Biopharm Co's PE Ratio (TTM) for today is calculated as:
TTY Biopharm Co's share price for today is NT$78.10.
TTY Biopharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$6.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TTY Biopharm Co EV-to-FCF Related Terms
TTY Biopharm Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's EV-to-FCF falls into.
TTY Biopharm Co's current Enterprise Value is NT$17,960 Mil.
TTY Biopharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,781 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a EV-to-FCF of 10.08 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TTY Biopharm Co and its competitors. This is 47% below median its historical median of 19.06. Over the past decade, TTY Biopharm Co's EV-to-FCF has ranged from 9.27 to 53.26. According to the industry distribution chart, TTY Biopharm Co ranks #146 out of 566 companies in the Drug Manufacturers industry, placing it in the top 25.8%.
Is TTY Biopharm Co's EV-to-FCF too high?
TTY Biopharm Co's current EV-to-FCF of 10.08 is 47% below median its 10-year median of 19.06. Over the past 10 years, this metric has ranged from a low of 9.27 to a high of 53.26. The Drug Manufacturers industry median EV-to-FCF is 20.95. TTY Biopharm Co's value of 10.08 is 51.9% below this industry median. Based on the distribution chart, TTY Biopharm Co ranks #146 out of 566 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #146 out of 566 companies for EV-to-FCF. This puts TTY Biopharm Co in the upper half of its industry. The industry median EV-to-FCF is 20.95. TTY Biopharm Co's value of 10.08 is 51.9% below this benchmark. Historically, TTY Biopharm Co's own EV-to-FCF has ranged from 9.27 to 53.26 over the past decade. While the company's 10-year median is 19.06 vs. the industry median of 20.95, TTY Biopharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.95, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current EV-to-FCF of 10.08 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current EV-to-FCF is 10.08, which is 47% below median its own 10-year median of 19.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$78.10 — trading 10.8% below its estimated fair value. The current EV-to-FCF is 10.08, which is 47% below median its 10-year median of 19.06 and 51.9% below the Drug Manufacturers industry median of 20.95. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current EV-to-FCF is 10.08 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$78.10 is trading 10.8% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
EV-to-FCF: 10.08 (47% below median its 10-year median of 19.06)
GF Value™: NT$87.56 vs. price of NT$78.10 (10.8% below fair value)
Industry Position: 51.9% below the Drug Manufacturers median (#146 of 566)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
